Aptadel Therapeutics raises 2 million euros and prepares a new round to bring the clinical phase stage
Aptadel Therapeutics takes another step forward in the development of its treatment for Ewing's sarcoma. The biotechnology company, based at the University of Barcelona Parc Científic de Barcelona (PCB-UB), has closed a bridge round of 2 million euros with the entry of the Japanese investment group Newsight Tech Angels, and gets an added injection of capital from its US investor, the Little Warrior Foundation (LWF).
It is a reflection of the trust the international community has in the project and gives development new impetus at a key stage of growth. project to the clinical phase stage of growth.
- Aptadel Therapeutics consigue dos millones de euros y prepara nueva ronda para impulsar el proyecto hacia las fases clínicas:
https://www.phmk.es/industria/aptadel-therapeutics-consigue-2-millones-de-euros-y-prepara-nueva-ronda-para-impulsar-el-proyecto-hacia-las-fases-clinicas - La catalana Aptadel Therapeutics obtiene 2 millones para su tratamiento del cáncer pediátrico:
https://www.elperiodico.com/es/economia/20260324/aptadel-therapeutics-ronda-2-millones-tratamiento-sarcoma-ewing-cancer-pediatrico-128309827 - Aptadel Therapeutics capta 2M€ per desenvolupar el seu fàrmac contra el sarcoma d'Edwin:
https://www.ara.cat/economia/farmaceutiques/aptadel-therapeutics-capta-2-m-desenvolupar-farmac-sarcoma-d-ewing_1_5687377.html - Aptadel Therapeutics cierra una ronda puente de 2 millones e incorpora un nuevo inversor:
https://www.europapress.es/catalunya/noticia-aptadel-therapeutics-cierra-ronda-puente-millones-incorpora-nuevo-inversor-20260324110925.html